Expert: Aducanumab Concerns Could Impact Implementation for Alzheimer Disease

Although she said it is unlikely that the FDA will retract the approval, prescribers could be reluctant to administer aducanumab to patients.

In an interview with Pharmacy Times, Pamela Spicer, senior analyst with Datamonitor at Informa Pharma Intelligence, said the various controversies surrounding the FDA approval of aducanumab could impact its implementation in health systems. Although she said it's unlikely that the FDA will retract the approval, she said prescribers could be reluctant to administer aducanumab to patients.

Several major health systems—The Cleveland Clinic, Mount Sinai Health System, and Providence Health in Washington State—have already announced that they will not administer aducanumab, according to reporting by The Wall Street Journal.1 This interview was filmed prior to these announcements.

REFERENCE

  1. Walker J. Cleveland Clinic, Mount Sinai and Providence Won't Give Biogen's New Alzheimer's Drug. Wall Street Journal. July 15, 2021. Accessed July 22, 2021. https://www.wsj.com/articles/cleveland-clinic-mount-sinai-wont-give-biogens-new-alzheimers-drug-11626366968